IQVIA Holdings Inc. IQV
Set alert
At close · Nov 2
After hours · Nov 2, 7:03 PM ET
- YTD
- +14.65%
- 1 year
- +19.39%
- Open
- 269.43
- Prev close
- 267.33
- Mkt cap
- 42.59B
- Vol
- 1.37M
- Avg vol
- 1.41M
- EPS
- 7.95
- P/E
- 32.51
- Div yield
- 0.00%
More statistics
- Low
- 257.35
- High
- 270.00
- Forward P/E
- 18.19
- Beta
- 1.17
- Short ratio
- 1.92
- Inst. own
- 103.08%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 4, 2027
- 50-d avg
- 266.09
- 200-d avg
- 209.52
- 1y target
- 311.47
6M chart
Events in this range
- May 5, 2026Earnings: 2.9; estimate 2.82; surprise 2.84%
- Jul 28, 2026Earnings: 3.15; estimate 3.03; surprise 3.96%
- Oct 14, 2026Rating: Stifel · Buy → Buy
- Oct 27, 2026Earnings: 3.34; estimate 3.26; surprise 2.45%
- Oct 28, 2026Rating: Baird · Outperform → Outperform
- Oct 28, 2026Rating: Evercore ISI Group · Outperform → Outperform
- Oct 28, 2026Rating: Truist Securities · Buy → Buy
- Oct 28, 2026Rating: JP Morgan · Overweight → Overweight
- Oct 29, 2026Rating: TD Cowen · Buy → Buy
Signals (30)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 16 hours ago |
| MACD: Sell Signal | Oct 30, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Overbought | Sep 2, 2026 | 2 months ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 20, 2026 | 2 months ago |
| RSI: Overbought | Aug 20, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 28, 2026 | 3 months ago |
| RSI: Overbought | Jul 28, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| RSI: Overbought | Jul 9, 2026 | 3 months ago |
| RSI: Overbought | Jul 1, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| SMA: Bullish | Jun 24, 2026 | 4 months ago |
| SMA: Bullish | Jun 24, 2026 | 4 months ago |
| SMA: Bearish | Jun 17, 2026 | 4 months ago |
| SMA: Bearish | Jun 17, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 5 months ago |
Newest 20 of 30.
Key statistics
- Market cap
- 42.58B
- Enterprise value
- 58.08B
- Trailing P/E
- 31.43
- Forward P/E
- 18.19
- PEG ratio
- 0.99
- Price / sales
- 2.46
- Price / book
- 6.39
- EPS (TTM)
- 8.22
- Beta
- 1.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 8.05%
- Revenue (TTM)
- 17.31B
- Revenue growth
- 8.00%
- Free cash flow
- 2.12B
- Total cash
- 2.42B
- Total debt
- 16.31B
- Return on equity
- 21.39%
- Shares outstanding
- 164.80M
- Short % of float
- 2.11%
- 50-day average
- 266.09
- 200-day average
- 209.52
Analyst view
Consensus: strong buy
- Target (low)
- 268.00
- Target (mean)
- 311.47
- Target (high)
- 346.00
- Strong buy2
- Buy16
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate 3.58.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | 3.60 | — | — | — |
| Oct 27, 2026 | Sep 30, 2026 | 3.26 | 3.34 | +0.08 | +2.45% |
| Jul 28, 2026 | Jun 30, 2026 | 3.03 | 3.15 | +0.12 | +3.96% |
| May 5, 2026 | Mar 31, 2026 | 2.82 | 2.90 | +0.08 | +2.84% |
| Feb 5, 2026 | Dec 31, 2025 | 3.40 | 3.42 | +0.02 | +0.59% |
| Oct 28, 2025 | Sep 30, 2025 | 2.98 | 3.00 | +0.02 | +0.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | TD Cowen | main | Buy | Buy |
| Oct 28, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 28, 2026 | Truist Securities | main | Buy | Buy |
| Oct 28, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Oct 28, 2026 | Baird | main | Outperform | Outperform |
| Oct 14, 2026 | Stifel | main | Buy | Buy |
About IQVIA Holdings Inc.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- iqvia.com
News
- TD Cowen Maintains Buy on IQVIA Holdings, Raises Price Target to $307
- Artisan Global Value Fund Q3 2026 Portfolio Discussion
- Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock
- JP Morgan Maintains Overweight on IQVIA Holdings, Raises Price Target to $325
- Truist Securities Maintains Buy on IQVIA Holdings, Raises Price Target to $346
- Evercore ISI Group Maintains Outperform on IQVIA Holdings, Raises Price Target to $310
- Baird Maintains Outperform on IQVIA Holdings, Raises Price Target to $328
- IQVIA Holdings Inc. $IQV Stock Purchased by Citizens Financial Group Inc. RI
- What IQVIA (IQV) Said on Its Q3 Earnings Call
- IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y
Your note
Sign in to keep a note on IQV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOUSBIB ARI B | Chief Executive Officer | Sale | Jul 28, 2026 | 1,379,240 |
| BRUEHLMAN RONALD E | Chief Financial Officer | Stock Award(Grant) | Feb 5, 2026 | 55,996 |
| DANHAKL JOHN G | Director | Stock Award(Grant) | Apr 22, 2026 | 0 |
| FEDOCK MICHAEL J. | Officer | Stock Award(Grant) | Feb 5, 2026 | 9,595 |
| GOGGINS COLLEEN A | Director | Stock Award(Grant) | Apr 22, 2026 | 14,453 |
| GRENFELL ALISTAIR | Officer | Stock Award(Grant) | Feb 5, 2026 | 24,124 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.83% | 14,549,693 | 3.76B | Jun 29, 2026 |
| Harris Associates L.P. | 7.39% | 12,183,830 | 3.15B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.62% | 10,905,053 | 2.82B | Jun 29, 2026 |
| State Street Corporation | 4.56% | 7,508,244 | 1.94B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.55% | 7,501,993 | 1.94B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 3.73% | 6,139,775 | 1.59B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.22% | 5,299,333 | 1.37B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.62% | 4,323,399 | 1.12B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.19% | 3,616,429 | 934.38M | Jun 29, 2026 |
| HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Select Fund | 1.58% | 2,605,500 | 673.18M | Jun 29, 2026 |
| HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Fund | 1.56% | 2,565,300 | 662.80M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 2,192,900 | 566.58M | Sep 29, 2026 |